You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Old and New Therapies for Sporotrichosis
Carol A. Kauffman
Clinical Infectious Diseases
Vol. 21, No. 4 (Oct., 1995), pp. 981-985
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4458950
Page Count: 5
Preview not available
The old therapies for sporotrichosis-saturated solution of potassium iodide (SSKI) and amphotericin B-have largely been supplanted by itraconazole treatment. Although SSKI is effective for the treatment of lymphocutaneous sporotrichosis, it is difficult to administer and is frequently associated with side effects; response rates of >90% are associated with itraconazole therapy for lymphocutaneous sporotrichosis. Patients with osteoarticular sporotrichosis rarely have systemic symptoms and can be effectively treated with a prolonged course of itraconazole, thus obviating the need for intravenous amphotericin B therapy with its associated toxic effects. Pulmonary sporotrichosis in patients with chronic obstructive pulmonary disease and disseminated sporotrichosis in patients infected with human immunodeficiency virus continue to be difficult therapeutic problems, but itraconazole appears to be at least as effective as amphotericin B as treatment for these forms of sporotrichosis.
Clinical Infectious Diseases © 1995 Oxford University Press